Breaking News Instant updates and real-time market news.

EW

Edwards Lifesciences

$190.70

0.71 (0.37%)

, ABT

Abbott

$79.51

-0.11 (-0.14%)

09:25
04/04/19
04/04
09:25
04/04/19
09:25

Credit Suisse med technology analysts to hold analyst/industry conference call

Medical Technology Analysts discuss Abbott Labs and Edwards Lifesciences mitral litigation on an Analyst/Industry conference call to be held on April 4 at 10:30 am.

EW

Edwards Lifesciences

$190.70

0.71 (0.37%)

ABT

Abbott

$79.51

-0.11 (-0.14%)

  • 04

    Apr

  • 17

    Apr

  • 26

    Apr

EW Edwards Lifesciences
$190.70

0.71 (0.37%)

03/22/19
ADAM
03/22/19
NO CHANGE
Target $1.1
ADAM
Buy
Neovasc court win in Germany removes overhang, says Canaccord
Canaccord analyst Jason Mills said the ruling yesterday from a German court in dismissing the claim to co-inventorship of the Tiara device made by Edwards Lifesciences' (EW) CardiAQ removes a litigation overhang for Neovasc (NVCN). Mills continues to view Neovasc as an "attractive, albeit admittedly risky," play on the Transcatheter Mitral Valve Repair sector and keeps a Buy rating and $1.10 price target on the shares.
03/25/19
LEHM
03/25/19
NO CHANGE
Target $160
LEHM
Overweight
Edwards Lifesciences price target raised to $160 from $150 at Barclays
Barclays analyst Kristen Stewart raised her price target for Edwards Lifesciences to $160 from $150 after the Partner 3 data that showed the Sapien 3 transcatheter aortic valve was superior to surgery in low risk patients. While the market was broadly expecting superiority, results were very good across the board and better than many expected, Stewart tells investors in a research note. The analyst, however, maintains an Underweight rating on Edwards Lifesciences. She believes the stock is more than pricing the TAVR opportunity and assuming success with mitral. "In this context, we think there could be some risk ahead," Stewart tells investors in a research note.
03/27/19
ADAM
03/27/19
NO CHANGE
Target $215
ADAM
Buy
CMS' TAVR coverage memo positive for Edwards Lifesciences, says Canaccord
Canaccord analyst Jason Mills reiterated a Buy rating on Edwards Lifesciences with a $215 price target, telling investors in a research note that he views the Centers for Medicare and Medicaid Services' proposed Transcatheter Aortic Valve Replacement decision memo as incrementally positive for the TAVR field in general, and an incremental positive for Edwards specifically. The new, proposed TAVR coverage memo, which Mills says is less stringent on specific, prior procedure requirements, updates the requirements for TAVR centers to maintain their status as a TAVR center, and requires the center perform at least 50 AVRs/year, including at least 20 TAVRs/year, or else at least 100 AVRs every two years, at least 40 of which need to be TAVR.
03/27/19
JPMS
03/27/19
NO CHANGE
Target $190
JPMS
Neutral
Edwards Lifesciences price target raised to $190 from $175 at JPMorgan
JPMorgan analyst Robbie Marcus raised his price target for Edwards Lifesciences to $190 from $175 and keeps a Neutral rating on the shares. The analyst says his doctor survey following the Annual Scientific Session is "very bullish" and supportive of "significant" transcatheter aortic valve replacement market growth in the U.S. Marcus expects TAVR volume growth to accelerate from 15% in 2018 to 19% in 2019 and 22% in 2020. Nonetheless, he remains Neutral on shares of Edwards at current valuation levels. The analyst wants to see evidence of a faster than expected acceleration in the U.S. market, or less share/price loss to competition before looking to revisit his rating.
ABT Abbott
$79.51

-0.11 (-0.14%)

01/29/19
MSCO
01/29/19
NO CHANGE
MSCO
Mitraclip presents Abbott upside regardless of suit outcome, says Morgan Stanley
Morgan Stanley analyst David Lewis noted that Abbott (ABT) filed a complaint in Delaware and various jurisdictions outside of the U.S. alleging Edwards' (EW) Pascal device infringes on Mitraclip's intellectual property. While stating that it is currently challenging to weigh in on the probability or likelihood of success, Lewis said he believes his estimates for Mitracllip growth in 2019 are likely conservative and that he sees it as a driver of upside to Abbott growth regardless of a potential injunction. It is reasonable to assume Edwards developed Pascal in full awareness of Mitraclip's patent portfolio, said Lewis, who added that "Pascal is the second most important catalyst this year from a sentiment perspective, but less of a contributor to topline growth" for Edwards.
03/22/19
BMOC
03/22/19
NO CHANGE
Target $204
BMOC
Outperform
Edwards Lifesciences price target raised to $204 from $190 at BMO Capital
BMO Capital analyst Joanne Wuensch raised her price target on Edwards Lifesciences (EW) to $204 and kept her Outperform rating while removing the stock from her Top Picks list after its 25% year-to-date run-up. While there are some mid-year catalysts for the company such as the outcomes from the CMS NationalCoverage Decision proposal on March 27, clinical data from Pascal, and patent litigation with Abbott (ABT) regarding Pascal, the analyst contends that some consolidation in the stock price would not be surprising.
03/26/19
PIPR
03/26/19
NO CHANGE
Target $165
PIPR
Overweight
Piper discusses 16% selloff in DexCom over past three trading days
Piper Jaffray analyst JP McKim says he's fielded a lot of investor questions with shares of DexCom (DXCM) down 16% over the last three trading days. The crux of the selloff is Abbott's (ABT) Libre 2.0 and whether it gets interoperable continuous glucose monitoring and if so, what that does to volumes and price, McKim tells investors in a research note. The analyst sees little risk to DexCom's volumes for given the market inflection for continuous glucose monitoring, but adds that if Libre gets iCGM "payers maybe push a little harder on price." McKim admits that "headline risk is building around the approval" but keeps an Overweight rating on DexCom shares with a $165 price target. Libre 2.0 getting iCGM is not fully priced in the stock at this point, but some of that risk certainly is, says McKim.
04/03/19
JPMS
04/03/19
NO CHANGE
Target $175
JPMS
Overweight
JPMorgan remains 'very bullish' on DexCom despite Libre 2.0 uncertainty
The latest DexCom (DXCM) controversy is "whirling speculation" around Abbott's (ABT) Libre 2.0 launch, JPMorgan analyst Robbie Marcus tells investors in a research note. The analyst keeps an Overweight rating on DexCom shares with a $175 price target but expects uncertainty over Libre 2.0 to remain an overhang until it receives U.S. approval. However, he remains "very bullish" on the shares and sees "significant upside" to 2019 estimates. DexComis the best positioned in diabetes longer-term, Marcus contends.

TODAY'S FREE FLY STORIES

VET

Vermilion Energy

$26.99

0.525 (1.98%)

07:12
04/18/19
04/18
07:12
04/18/19
07:12
Downgrade
Vermilion Energy rating change  »

Vermilion Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

KEY

KeyCorp

$17.17

0.27 (1.60%)

07:12
04/18/19
04/18
07:12
04/18/19
07:12
Hot Stocks
KeyCorp sees FY19 net interest income $4B-$4.1B, noninterest income $2.5B-$2.6B »

In slides being presented…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

  • 13

    May

  • 23

    May

SBUX

Starbucks

$75.14

-0.57 (-0.75%)

07:12
04/18/19
04/18
07:12
04/18/19
07:12
Recommendations
Starbucks analyst commentary  »

Starbucks price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

HUSKF

Husky Energy

07:11
04/18/19
04/18
07:11
04/18/19
07:11
Upgrade
Husky Energy rating change  »

Husky Energy upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VKTX

Viking Therapeutics

$8.60

-0.61 (-6.62%)

07:11
04/18/19
04/18
07:11
04/18/19
07:11
Recommendations
Viking Therapeutics analyst commentary  »

Viking bear thesis based…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    May

  • 09

    May

BX

Blackstone

$35.91

-0.08 (-0.22%)

07:10
04/18/19
04/18
07:10
04/18/19
07:10
Earnings
Blackstone reports Q1 EPS 71c, consensus 53c »

Reports Q1 revenue $2.02B…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

  • 11

    Jun

07:10
04/18/19
04/18
07:10
04/18/19
07:10
General news
FX Update: The dollar has traded generally firmer »

FX Update: The dollar has…

VCEL

Vericel

$16.28

-2.25 (-12.14%)

07:09
04/18/19
04/18
07:09
04/18/19
07:09
Hot Stocks
Vericel appoints Paul Wotton, Ph.D., as CEO »

Obsidian Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

PM

Philip Morris

$85.49

-0.71 (-0.82%)

07:09
04/18/19
04/18
07:09
04/18/19
07:09
Hot Stocks
Philip Morris reports Q1 cigarette, heated tobacco unit shipment volume up 1.1% »

Reports cigarette and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

  • 01

    May

  • 06

    May

ENV

Envestnet

$69.17

-0.39 (-0.56%)

07:09
04/18/19
04/18
07:09
04/18/19
07:09
Initiation
Envestnet initiated  »

Envestnet initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    May

  • 05

    Jun

REXR

Rexford Industrial

$35.78

-0.325 (-0.90%)

07:09
04/18/19
04/18
07:09
04/18/19
07:09
Hot Stocks
Rexford Industrial acquires four industrial properties for $84.5M »

Rexford Industrial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 04

    Jun

POOL

Pool Corp.

$169.00

-1.63 (-0.96%)

07:08
04/18/19
04/18
07:08
04/18/19
07:08
Earnings
Breaking Earnings news story on Pool Corp. »

Pool Corp. raises FY19…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

  • 01

    May

  • 05

    Jun

  • 13

    Nov

SLB

Schlumberger

$47.39

-0.06 (-0.13%)

07:08
04/18/19
04/18
07:08
04/18/19
07:08
Hot Stocks
Schlumberger CEO expects oil market sentiments to 'steadily improve' in 2019 »

Schlumberger CEO Paal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

  • 06

    May

  • 22

    May

  • 13

    Nov

GOLD

Barrick Gold

$13.20

-0.06 (-0.45%)

, NEM

Newmont Mining

$34.18

-0.58 (-1.67%)

07:07
04/18/19
04/18
07:07
04/18/19
07:07
Hot Stocks
Barrick Gold reports preliminary Q1 sales of 1.37M ounces of gold »

After setting a…

GOLD

Barrick Gold

$13.20

-0.06 (-0.45%)

NEM

Newmont Mining

$34.18

-0.58 (-1.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 08

    May

POOL

Pool Corp.

$169.00

-1.63 (-0.96%)

07:07
04/18/19
04/18
07:07
04/18/19
07:07
Earnings
Pool Corp. reports Q1 ex-items EPS 59c, consensus 65c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

  • 01

    May

  • 05

    Jun

  • 13

    Nov

ACB

Aurora Cannabis

$8.95

0.11 (1.24%)

07:06
04/18/19
04/18
07:06
04/18/19
07:06
Hot Stocks
Aurora Cannabis provides update on German cannabis production tender »

Aurora Cannabis confirmed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLB

Schlumberger

$47.39

-0.06 (-0.13%)

07:06
04/18/19
04/18
07:06
04/18/19
07:06
Earnings
Schlumberger reports Q1 EPS 30c, consensus 30c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

  • 06

    May

  • 22

    May

  • 13

    Nov

SNGX

Soligenix

$0.83

0.03 (3.75%)

07:06
04/18/19
04/18
07:06
04/18/19
07:06
Hot Stocks
Soligenix reaches enrollment milestone in Phase 3 trial of SGX942 »

Soligenix has reached an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PM

Philip Morris

$85.49

-0.71 (-0.82%)

07:05
04/18/19
04/18
07:05
04/18/19
07:05
Hot Stocks
Breaking Hot Stocks news story on Philip Morris »

Philip Morris still sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

  • 01

    May

  • 06

    May

RCI

Rogers Communications

$53.15

-0.14 (-0.26%)

07:04
04/18/19
04/18
07:04
04/18/19
07:04
Earnings
Rogers Communications reports Q1 adj. EPS C$0.78 vs. C$0.90 last year »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

  • 14

    May

  • 23

    May

DWDP

DowDuPont

$39.20

-0.04 (-0.10%)

07:04
04/18/19
04/18
07:04
04/18/19
07:04
Hot Stocks
DowDuPont provides update on Q1 performance »

DowDuPont is providing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 29

    May

BX

Blackstone

$35.91

-0.08 (-0.22%)

07:04
04/18/19
04/18
07:04
04/18/19
07:04
Hot Stocks
Blackstone announces conversion to corporation »

Blackstone Chairman and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

  • 11

    Jun

PM

Philip Morris

$85.49

-0.71 (-0.82%)

07:04
04/18/19
04/18
07:04
04/18/19
07:04
Earnings
Philip Morris sees FY19 reported EPS at least $4.87, consensus $5.09 »

This full-year guidance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

  • 01

    May

  • 06

    May

WTR

Aqua America

$34.83

-1.075 (-2.99%)

07:03
04/18/19
04/18
07:03
04/18/19
07:03
Syndicate
Aqua America 32.5M share Secondary priced at $34.62 »

Goldman Sachs, RBC…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 03

    May

  • 18

    Apr

PM

Philip Morris

$85.49

-0.71 (-0.82%)

07:01
04/18/19
04/18
07:01
04/18/19
07:01
Earnings
Philip Morris reports Q1 adjusted EPS $1.09, consensus 97c »

Reports Q1 revenue $6.8B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

  • 01

    May

  • 06

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.